Barbara Seliger

Q: What Schools Are Affiliated With Barbara Seliger

Barbara Seliger is affiliated with the following schools: Martin Luther University of Halle-Wittenberg, University of California, Berkeley, University of Göttingen, Stanford University, University of California, San Francisco, Technical University of Munich, Witten/Herdecke University

Barbara Seliger's AcademicInfluence.com Rankings

Barbara Seliger

Biology

#9423

World Rank

#12628

Historical Rank

Immunology

#563

World Rank

#582

Historical Rank

biology Degrees

Download Badge

Biology

Barbara Seliger's Degrees

Bachelors Biology University of California, Berkeley
PhD Immunology Stanford University

Similar Degrees You Can Earn

Best Online Bachelor's in Biology 2025

Why Is Barbara Seliger Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Barbara Seliger's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

LDHA-Associated Lactic Acid Production Blunts Tumor Immunosurveillance by T and NK Cells. (2016) (889)
Genes for epidermal growth factor receptor, transforming growth factor alpha, and epidermal growth factor and their expression in human gliomas in vivo. (1991) (707)
Antigen-processing machinery breakdown and tumor growth. (2000) (486)
Two tyrosinase nonapeptides recognized on HLA‐A2 melanomas by autologous cytolytic T lymphocytes (1994) (441)
Cancer immunotherapy: Opportunities and challenges in the rapidly evolving clinical landscape. (2017) (398)
Dengue virus infection of human endothelial cells leads to chemokine production, complement activation, and apoptosis. (1998) (394)
Classification of current anticancer immunotherapies (2014) (357)
Hydrogen peroxide – production, fate and role in redox signaling of tumor cells (2015) (338)
The immunomodulatory capacity of mesenchymal stem cells. (2012) (296)
HLA class I antigen abnormalities and immune escape by malignant cells. (2002) (270)
Defects in the Human Leukocyte Antigen Class I Antigen Processing Machinery in Head and Neck Squamous Cell Carcinoma: Association with Clinical Outcome (2005) (248)
Tumor-Specific T Cell Activation by Recombinant Immunoreceptors: CD3ζ Signaling and CD28 Costimulation Are Simultaneously Required for Efficient IL-2 Secretion and Can Be Integrated Into One Combined CD28/CD3ζ Signaling Receptor Molecule1 (2001) (236)
TAP off--tumors on. (1997) (233)
A Critical Requirement of Interferon γ-mediated Angiostasis for Tumor Rejection by CD8+ T Cells (2003) (216)
Inhibition of Tumor-Derived Prostaglandin-E2 Blocks the Induction of Myeloid-Derived Suppressor Cells and Recovers Natural Killer Cell Activity (2014) (214)
Immune escape of melanoma: first evidence of structural alterations in two distinct components of the MHC class I antigen processing pathway. (2001) (211)
Tumors as elusive targets of T-cell-based active immunotherapy. (2003) (210)
Characterization of the major histocompatibility complex class I deficiencies in B16 melanoma cells. (2001) (203)
Engineering antigen-specific primary human NK cells against HER-2 positive carcinomas (2008) (168)
Heterogeneous expression of the tumor-associated antigens RAGE-1, PRAME, and glycoprotein 75 in human renal cell carcinoma: candidates for T-cell-based immunotherapies? (1998) (164)
A critical requirement of interferon gamma-mediated angiostasis for tumor rejection by CD8+ T cells. (2003) (156)
Defining the critical hurdles in cancer immunotherapy (2011) (152)
Molecular mechanisms of MHC class I abnormalities and APM components in human tumors (2008) (152)
5-aza-2'-deoxycytidine-induced expression of functional cancer testis antigens in human renal cell carcinoma: immunotherapeutic implications. (2002) (149)
MHC class I antigen processing pathway defects, ras mutations and disease stage in colorectal carcinoma (2004) (142)
The role of classical and non-classical HLA class I antigens in human tumors. (2012) (141)
Functional role of human leukocyte antigen-G up-regulation in renal cell carcinoma. (2003) (135)
Small interfering RNA (siRNA) inhibits the expression of the Her2/neu gene, upregulates HLA class I and induces apoptosis of Her2/neu positive tumor cell lines (2004) (134)
Analysis of the major histocompatibility complex class I antigen presentation machinery in normal and malignant renal cells: evidence for deficiencies associated with transformation and progression. (1996) (133)
Immune signature of tumor infiltrating immune cells in renal cancer (2015) (130)
Biology of HLA-G in cancer: a candidate molecule for therapeutic intervention? (2011) (130)
Upregulation of Major Histocompatibility Complex Class I on Liver Cells by Hepatitis C Virus Core Protein via p53 and TAP1 Impairs Natural Killer Cell Cytotoxicity (2003) (130)
Identification of genetic determinants of breast cancer immune phenotypes by integrative genome-scale analysis (2017) (129)
Multiparametric immune profiling in HPV- oral squamous cell cancer. (2017) (128)
Molecular mechanisms of HLA class I antigen abnormalities following viral infection and transformation (2006) (126)
Deficient expression of components of the MHC class I antigen processing machinery in human cervical carcinoma. (2001) (124)
T-cell activation by recombinant receptors: CD28 costimulation is required for interleukin 2 secretion and receptor-mediated T-cell proliferation but does not affect receptor-mediated target cell lysis. (2001) (121)
HER-2/neu-Mediated Regulation of Components of the MHC Class I Antigen-Processing Pathway (2004) (121)
Immune Modulatory microRNAs Involved in Tumor Attack and Tumor Immune Escape (2017) (118)
AML1-ETO requires enhanced C/D box snoRNA/RNP formation to induce self-renewal and leukaemia (2017) (118)
B7-H4 Expression in Human Melanoma: Its Association with Patients' Survival and Antitumor Immune Response (2011) (117)
Characterization of human lymphocyte antigen class I antigen-processing machinery defects in renal cell carcinoma lesions with special emphasis on transporter-associated with antigen-processing down-regulation. (2003) (117)
Warburg phenotype in renal cell carcinoma: High expression of glucose‐transporter 1 (GLUT‐1) correlates with low CD8+ T‐cell infiltration in the tumor (2011) (114)
Tumor-Specific T Cell Activation by Recombinant Immunoreceptors: CD3ζ Signaling and CD28 Costimulation Are Simultaneously Required for Efficient IL-2 Secretion and Can Be Integrated into One Combined CD28/CD3ζ Signaling Receptor Molecule (2004) (112)
NKp46 Receptor‐Mediated Interferon‐&ggr; Production by Natural Killer Cells Increases Fibronectin 1 to Alter Tumor Architecture and Control Metastasis (2018) (110)
Down-regulation of HLA class I antigen processing molecules: an immune escape mechanism of renal cell carcinoma? (2004) (106)
HLA-G and MIC expression in tumors and their role in anti-tumor immunity. (2003) (106)
Strategies of Tumor Immune Evasion (2012) (102)
The Role of Immune Escape and Immune Cell Infiltration in Breast Cancer (2018) (101)
Common cancer biomarkers. (2006) (100)
Association of HLA class I antigen abnormalities with disease progression and early recurrence in prostate cancer (2010) (99)
Control of CREB expression in tumors: from molecular mechanisms and signal transduction pathways to therapeutic target (2016) (98)
Down‐regulation of the MHC class I antigen‐processing machinery after oncogenic transformation of murine fibroblasts (1998) (97)
Reduced membrane major histocompatibility complex class I density and stability in a subset of human renal cell carcinomas with low TAP and LMP expression. (1996) (95)
The complex role of B7 molecules in tumor immunology. (2008) (95)
Restoration of the expression of transporters associated with antigen processing in lung carcinoma increases tumor-specific immune responses and survival. (2005) (90)
Chapter 7 IFN Inducibility of Major Histocompatibility Antigens in Tumors (2008) (87)
Tuning tumor-specific T-cell activation: a matter of costimulation? (2002) (86)
Cellular immunity to the Her-2/neu protooncogene. (2002) (83)
Design of proteome‐based studies in combination with serology for the identification of biomarkers and novel targets (2002) (82)
The expression, function, and clinical relevance of B7 family members in cancer (2012) (80)
The MAPK Pathway Is a Predominant Regulator of HLA-A Expression in Esophageal and Gastric Cancer (2013) (80)
Differential γ-Interferon Response of Human Colon Carcinoma Cells: Inhibition of Proliferation and Modulation of Immunogenicity as Independent Effects of γ-Interferon on Tumor Cell Growth (1985) (80)
Targeting of tumor associated antigens in renal cell carcinoma using proteome‐based analysis and their clinical significance (2002) (79)
Identification of metabolic enzymes in renal cell carcinoma utilizing PROTEOMEX analyses. (2003) (77)
Functional deficiencies of components of the MHC class I antigen pathway in human tumors of epithelial origin (2000) (76)
Novel insights into the molecular mechanisms of HLA class I abnormalities (2012) (76)
The role of the miR‐148/‐152 family in physiology and disease (2017) (75)
Clinical relevance of the tumor microenvironment and immune escape of oral squamous cell carcinoma (2016) (74)
Frequent loss of HLA-A2 expression in metastasizing ovarian carcinomas associated with genomic haplotype loss and HLA-A2-restricted HER-2/neu-specific immunity. (2006) (74)
Regulatory T cells with reduced repressor capacities are extensively amplified in pulmonary sarcoid lesions and sustain granuloma formation. (2011) (73)
Thyroid hormone receptor/c-erbA: control of commitment and differentiation in the neuronal/chromaffin progenitor line PC12 (1993) (70)
Basis of PD1/PD-L1 Therapies (2019) (69)
The role of microRNAs in the control of innate immune response in cancer. (2014) (68)
Different regulation of MHC Class I antigen processing components in human tumors (2008) (68)
Molecular analysis of the erythropoietin receptor system in patients with polycythaemia vera (1994) (67)
IFN-gamma-mediated coordinated transcriptional regulation of the human TAP-1 and LMP-2 genes in human renal cell carcinoma. (1997) (66)
Cellular immune response to human renal‐cell carcinomas: Definition of a common antigen recognized by HLA‐A2‐restricted cytotoxic T‐Lymphocyte (CTL) clones (1994) (66)
Implementing liquid biopsies into clinical decision making for cancer immunotherapy (2017) (66)
What turns CREB on? And off? And why does it matter? (2020) (65)
Downregulation of the constitutive tapasin expression in human tumor cells of distinct origin and its transcriptional upregulation by cytokines. (2001) (64)
HER‐2/neu is expressed in human renal cell carcinoma at heterogeneous levels independently of tumor grading and staging and can be recognized by HLA‐A2.1‐restricted cytotoxic T lymphocytes (2000) (64)
Identification and validation of novel ERBB2 (HER2, NEU) targets including genes involved in angiogenesis (2005) (63)
HER2/HER3 Signaling Regulates NK Cell-Mediated Cytotoxicity via MHC Class I Chain-Related Molecule A and B Expression in Human Breast Cancer Cell Lines (2012) (62)
Redox proteomics: Methods for the identification and enrichment of redox‐modified proteins and their applications (2016) (61)
Retroviral mutants efficiently expressed in embryonal carcinoma cells. (1986) (61)
The Transporter Associated With Antigen Processing (TAP): Structural Integrity, Expression, Function, and Its Clinical Relevance (2001) (60)
Bipartite regulation of different components of the MHC class I antigen-processing machinery during dendritic cell maturation. (2001) (59)
Analysis of the p53 and MDM‐2 gene in acute myeloid leukemia (1996) (57)
HLA class II antigen-processing pathway in tumors: Molecular defects and clinical relevance (2017) (57)
Expression, regulation and function of the ISGylation system in prostate cancer (2009) (57)
Association of IFN-γ Signal Transduction Defects with Impaired HLA Class I Antigen Processing in Melanoma Cell Lines (2011) (57)
NKp46 Receptor-Mediated Interferon-γ Production by Natural Killer Cells Increases Fibronectin 1 to Alter Tumor Architecture and Control Metastasis (2018) (57)
CD4+ T cell‐mediated HER‐2/neu‐specific tumor rejection in the absence of B cells (2004) (56)
HER-2/neu mediated down-regulation of MHC class I antigen processing prevents CTL-mediated tumor recognition upon DNA vaccination in HLA-A2 transgenic mice (2009) (56)
Suppression of MHC class I antigens in oncogenic transformants: association with decreased recognition by cytotoxic T lymphocytes. (1996) (56)
Heat shock protein expression and anti‐heat shock protein reactivity in renal cell carcinoma (2002) (56)
Clinical relevance of miR-mediated HLA-G regulation and the associated immune cell infiltration in renal cell carcinoma (2015) (55)
Melanoma-restricted genes (2004) (55)
T cell recognition of HLA‐A2 restricted tumor antigens is impaired by the oncogene HER2 (2011) (54)
Reduced Immunosuppressive Properties of Axitinib in Comparison with Other Tyrosine Kinase Inhibitors* (2013) (53)
HLA-dependent tumour development: a role for tumour associate macrophages? (2013) (53)
Expression and regulation of non-classical HLA-G in renal cell carcinoma. (2008) (52)
Ubiquitin COOH-Terminal Hydrolase 1: A Biomarker of Renal Cell Carcinoma Associated with Enhanced Tumor Cell Proliferation and Migration[?Q1: Running head: UCHL1, a Biomarker of RCC. Short title OK?Q1] (2007) (52)
“UniCAR”-modified off-the-shelf NK-92 cells for targeting of GD2-expressing tumour cells (2020) (52)
High Frequency of Functionally Active Melan-A–Specific T Cells in a Patient with Progressive Immunoproteasome-Deficient Melanoma (2004) (52)
Integrated analysis of the immunological and genetic status in and across cancer types: impact of mutational signatures beyond tumor mutational burden (2018) (51)
Immunoprophylactic and immunotherapeutic control of hormone receptor-positive breast cancer (2020) (51)
Comparison of the established standard complement-dependent cytotoxicity and flow cytometric crossmatch assays with a novel ELISA-based HLA crossmatch procedure. (2006) (51)
CD4+ tumor-infiltrating lymphocytes in cervical cancer recognize HLA-DR-restricted peptides provided by human papillomavirus-E7. (1999) (51)
Clonal Evolution Including Partial Loss of Human Leukocyte Antigen Genes Favoring Extramedullary Acute Myeloid Leukemia Relapse After Matched Related Allogeneic Hematopoietic Stem Cell Transplantation (2012) (50)
Tumor-induced escape mechanisms and their association with resistance to checkpoint inhibitor therapy (2019) (49)
Nectin4 is a novel TIGIT ligand which combines checkpoint inhibition and tumor specificity (2020) (48)
Altered detoxification status and increased resistance to oxidative stress by K-ras transformation. (2008) (48)
Induction of immunogenicity of a human renal‐cell carcinoma cell line by TAP1‐gene transfer (1999) (47)
A systematic approach to biomarker discovery; Preamble to "the iSBTc-FDA taskforce on immunotherapy biomarkers" (2008) (46)
Molecular analysis of the HLA-A2 antigen loss by melanoma cells SK-MEL-29.1.22 and SK-MEL-29.1.29. (1998) (46)
Synergistic effects of IL-4 and TNFα on the induction of B7-H1 in renal cell carcinoma cells inhibiting allogeneic T cell proliferation (2014) (45)
Switching off HER-2/neu in a tetracycline-controlled mouse tumor model leads to apoptosis and tumor-size-dependent remission. (2003) (45)
Non-classical HLA-class I expression in serous ovarian carcinoma: Correlation with the HLA-genotype, tumor infiltrating immune cells and prognosis (2015) (44)
Distinct molecular mechanisms leading to deficient expression of ER-resident aminopeptidases in melanoma (2010) (44)
Combinatorial Approaches With Checkpoint Inhibitors to Enhance Anti-tumor Immunity (2019) (43)
T-cell Responses in the Microenvironment of Primary Renal Cell Carcinoma—Implications for Adoptive Cell Therapy (2018) (43)
Combined analysis of transcriptome and proteome data as a tool for the identification of candidate biomarkers in renal cell carcinoma (2009) (43)
Disentangling the relationship between tumor genetic programs and immune responsiveness. (2016) (43)
High variation of individual soluble serum CD30 levels of pre-transplantation patients: sCD30 a feasible marker for prediction of kidney allograft rejection? (2007) (42)
Constitutive and IFN-gamma regulated expression of IL-7 and IL-15 in human renal cell cancer. (1999) (42)
Future perspectives in melanoma research: meeting report from the “Melanoma Bridge”: Napoli, December 3rd–6th 2014 (2013) (42)
Identification of novel microRNAs regulating HLA-G expression and investigating their clinical relevance in renal cell carcinoma (2016) (41)
Expression and function of the peptide transporters in escape variants of human renal cell carcinomas. (1997) (41)
Coordinate downregulation of multiple MHC class I antigen processing genes in chemical-induced murine tumor cell lines of distinct origin. (2000) (41)
Identification of markers for the selection of patients undergoing renal cell carcinoma‐specific immunotherapy (2003) (40)
Identification of fatty acid binding proteins as markers associated with the initiation and/or progression of renal cell carcinoma (2005) (40)
HNRNPR Regulates the Expression of Classical and Nonclassical MHC Class I Proteins (2016) (39)
Altered expression of nonclassical HLA class Ib antigens in human renal cell carcinoma and its association with impaired immune response. (2003) (38)
Aminopeptidase N (APN)/CD13-dependent CXCR4 downregulation is associated with diminished cell migration, proliferation and invasion (2008) (37)
Acquired Immune Resistance Follows Complete Tumor Regression without Loss of Target Antigens or IFNγ Signaling. (2017) (36)
Checkpoint Inhibitors and Their Application in Breast Cancer (2016) (36)
Candidate biomarkers in renal cell carcinoma (2007) (36)
Structure, expression and function of HLA-G in renal cell carcinoma. (2007) (36)
Identification of E2F1 as an Important Transcription Factor for the Regulation of Tapasin Expression* (2010) (36)
Molecular mechanisms of HLA class I‐mediated immune evasion of human tumors and their role in resistance to immunotherapies (2016) (35)
HLA-E expression and its clinical relevance in human renal cell carcinoma (2016) (35)
Viral transfer, transcription, and rescue of a selectable myeloproliferative sarcoma virus in embryonal cell lines: expression of the mos oncogene (1986) (34)
Low frequency of HLA haplotype loss associated with loss of heterozygocity in chromosome region 6p21 in clear renal cell carcinomas (2004) (34)
Correlation of HLA-A02* genotype and HLA class I antigen down-regulation with the prognosis of epithelial ovarian cancer (2012) (34)
Strong immunogenic potential of a B7 retroviral expression vector: generation of HLA-B7-restricted CTL response against selectable marker genes. (1998) (33)
The link between MHC class I abnormalities of tumors, oncogenes, tumor suppressor genes, and transcription factors (2014) (33)
Blood immune cell biomarkers in lung cancer (2018) (33)
Future perspectives in melanoma research. Meeting report from the “Melanoma Bridge. Napoli, December 2nd-4th 2012” (2013) (33)
Analysis of the MHC Class I Antigen Presentation Machinery in Human Embryonal Carcinomas: Evidence for Deficiencies in TAP, LMP and MHC Class I Expression and their Upregulation by IFN‐γ (1997) (33)
Loss of interferon‐γ inducibility of the MHC class II antigen processing pathway in head and neck cancer: evidence for post‐transcriptional as well as epigenetic regulation (2008) (32)
Recognition of Human Renal Cell Carcinoma and Melanoma by HLA‐A2‐Restricted Cytotoxic T Lymphocytes is Mediated by Shared Peptide Epitopes and Up‐Regulated by Interferon‐γ (1996) (31)
Increased tumorigenicity, but unchanged immunogenicity, of transporter for antigen presentation 1-deficient tumors. (2002) (31)
Multiple Levels of MHC Class I Down‐Regulation by ras Oncogenes (1996) (31)
HER-2/neu Mediates Oncogenic Transformation via Altered CREB Expression and Function (2013) (31)
Antitumour and immune-adjuvant activities of protein-tyrosine kinase inhibitors. (2010) (30)
High frequency of functionally active Melan-A specific T cells in a patient with progressive immunoproteasome-deficient melanoma (2004) (29)
Contrasting Effects of the Cytotoxic Anticancer Drug Gemcitabine and the EGFR Tyrosine Kinase Inhibitor Gefitinib on NK Cell-Mediated Cytotoxicity via Regulation of NKG2D Ligand in Non-Small-Cell Lung Cancer Cells (2015) (29)
Soluble CD30 serum level--an adequate marker for allograft rejection of solid organs? (2007) (29)
Blood Immune Cell Biomarkers in Patient With Lung Cancer Undergoing Treatment With Checkpoint Blockade (2019) (29)
Longitudinal analysis of the T‐cell receptor (TCR)‐VA and ‐VB repertoire in CD8+ T cells from individuals immunized with recombinant hepatitis B surface antigen (2002) (28)
Epigenetic control of the ubiquitin carboxyl terminal hydrolase 1 in renal cell carcinoma (2009) (28)
Molecular mechanism of CHRDL1-mediated X-linked megalocornea in humans and in Xenopus model. (2015) (27)
HER-2/neu-mediated Down-regulation of Biglycan Associated with Altered Growth Properties* (2012) (27)
Systematic Comparative Protein Expression Profiling of Clear Cell Renal Cell Carcinoma (2009) (27)
Opinion: Standardizing gene product nomenclature—a call to action (2021) (27)
Distinct von Hippel-Lindau gene and hypoxia-regulated alterations in gene and protein expression patterns of renal cell carcinoma and their effects on metabolism (2015) (27)
Ontogeny and Oncogenesis Balance the Transcriptional Profile of Renal Cell Cancer (2004) (26)
Overexpressed vs mutated Kras in murine fibroblasts: a molecular phenotyping study (2009) (26)
Latent Cytomegalovirus Infection in Rheumatoid Arthritis and Increased Frequencies of Cytolytic LIR‐1+CD8+ T Cells (2015) (26)
Heat shock proteins in renal cell carcinomas. (2005) (26)
A gene expression signature associated with B cells predicts benefit from immune checkpoint blockade in lung adenocarcinoma (2021) (25)
Functional cysteine‐less subunits of the transporter associated with antigen processing (TAP1 and TAP2) by de novo gene assembly (2003) (24)
Individual effects of different selenocompounds on the hepatic proteome and energy metabolism of mice. (2017) (24)
Identification of 14-3-3β Gene as a Novel miR-152 Target Using a Proteome-based Approach* (2014) (24)
Immunotherapy biomarkers 2016: overcoming the barriers (2017) (24)
Colorectal Carcinogenesis: Connecting K-RAS–Induced Transformation and CREB Activity In Vitro and In Vivo (2015) (23)
The Dark Side of Dendritic Cells: Development and Exploitation of Tolerogenic Activity That Favor Tumor Outgrowth and Immune Escape (2013) (23)
Adiponectin and Its Receptors Are Differentially Expressed in Human Tissues and Cell Lines of Distinct Origin (2017) (23)
Long‐term freedom from recurrence in 2 stage IV melanoma patients following vaccination with tyrosinase peptides (2002) (23)
High frequency of a non-functional TAP1/LMP2 promoter polymorphism in human tumors. (2002) (23)
Detection of renal cell carcinoma-associated markers via proteome- and other 'ome'-based analyses. (2003) (23)
Identification and characterization of human leukocyte antigen class I ligands in renal cell carcinoma cells (2011) (23)
Different maturation cocktails provide dendritic cells with different chemoattractive properties (2015) (23)
Systematic evaluation of immune regulation and modulation (2017) (22)
A Proteomic View at T Cell Costimulation (2012) (22)
Cloning and functional analyses of the mouse tapasin promoter (2003) (22)
Expression of neutral endopeptidase (NEP/CD10) on pancreatic tumor cell lines, pancreatitis and pancreatic tumor tissues (2007) (22)
Partial restoration of pre‐transformation levels of lysyl oxidase and transin mRNAs in phenotypic ras revertants (1995) (22)
The role of HLA-G for protection of human renal cell-carcinoma cells from immune-mediated lysis: implications for immunotherapies. (2003) (21)
The myeloproliferative sarcoma virus retains transforming functions after introduction of a dominant selectable marker gene. (1986) (21)
Identification of a novel lncRNA induced by the nephrotoxin ochratoxin A and expressed in human renal tumor tissue (2018) (21)
CREB1 is affected by the microRNAs miR-22-3p, miR-26a-5p, miR-27a-3p, and miR-221-3p and correlates with adverse clinicopathological features in renal cell carcinoma (2020) (21)
Epstein–Barr Virus—Associated Malignancies and Immune Escape: The Role of the Tumor Microenvironment and Tumor Cell Evasion Strategies (2021) (21)
Multiple readout assay for hormonal (androgenic and antiandrogenic) and cytotoxic activity of plant and fungal extracts based on differential prostate cancer cell line behavior. (2014) (20)
Immune Therapy Resistance and Immune Escape of Tumors (2021) (20)
Fast Dendritic Cells Stimulated with Alternative Maturation Mixtures Induce Polyfunctional and Long-Lasting Activation of Innate and Adaptive Effector Cells with Tumor-Killing Capabilities (2013) (20)
Monitoring peri-operative immune suppression in renal cancer patients. (2011) (20)
Identification of miR-200a-5p targeting the peptide transporter TAP1 and its association with the clinical outcome of melanoma patients (2020) (20)
The two sides of HER2/neu: immune escape versus surveillance. (2013) (19)
Role of microRNAs on HLA-G expression in human tumors. (2016) (19)
Future perspectives in melanoma research: meeting report from the “Melanoma Bridge”, Napoli, December 5th-8th 2013 (2014) (19)
Gene transfer into brain tumor cell lines: Reporter gene expression using various cellular and viral promoters (1990) (19)
HLA Class I Antigen Processing Machinery Defects in Cancer Cells-Frequency, Functional Significance, and Clinical Relevance with Special Emphasis on Their Role in T Cell-Based Immunotherapy of Malignant Disease. (2020) (19)
PD-L1 targeting and subclonal immune escape mediated by PD-L1 mutations in metastatic colorectal cancer (2021) (18)
Influence of Ki‐ras‐driven oncogenic transformation on the protein network of murine fibroblasts (2007) (18)
Identification of microRNAs Targeting the Transporter Associated with Antigen Processing TAP1 in Melanoma (2020) (18)
Heterogeneous expression and functional relevance of the ubiquitin carboxyl‐terminal hydrolase L1 in melanoma (2013) (18)
Impaired Transporter Associated with Antigen Processing (TAP) Function Attributable to a Single Amino Acid Alteration in the Peptide TAP Subunit TAP11 (2003) (18)
Human leucocyte antigen class I in hormone receptor-positive, HER2-negative breast cancer: association with response and survival after neoadjuvant chemotherapy (2019) (18)
c-Myc and EBV–LMP1: two opposing regulators of the HLA class I antigen presentation machinery in epithelial cells (2012) (18)
Mapping and expression pattern analysis of key components of the major histocompatibility complex class I antigen processing and presentation pathway in a representative human renal cell carcinoma cell line (2001) (18)
Biglycan-mediated upregulation of MHC class I expression in HER-2/neu-transformed cells (2017) (17)
Analysis of HLA class I-II haplotype frequency and segregation in a cohort of patients with advanced stage ovarian cancer. (2007) (17)
Identification of sequences in the human peptide transporter subunit TAP1 required for transporter associated with antigen processing (TAP) function. (2001) (17)
CIITA versus IFN-γ induced MHC class II expression in head and neck cancer cells (2009) (17)
Comparative Expression Profiling of Distinct T Cell Subsets Undergoing Oxidative Stress (2012) (17)
Cancer Neoepitopes for Immunotherapy: Discordance Between Tumor-Infiltrating T Cell Reactivity and Tumor MHC Peptidome Display (2019) (17)
Accumulation of tolerogenic human 6-sulfo LacNAc dendritic cells in renal cell carcinoma is associated with poor prognosis (2015) (17)
Differential gamma-interferon response of human colon carcinoma cells: inhibition of proliferation and modulation of immunogenicity as independent effects of gamma-interferon on tumor cell growth. (1985) (16)
TGF-β inducible epithelial-to-mesenchymal transition in renal cell carcinoma (2019) (16)
Tumor-dependent Effects of Proteoglycans and Various Glycosaminoglycan Synthesizing Enzymes and Sulfotransferases on Patients' Outcome. (2019) (16)
Linking CREB function with altered metabolism in murine fibroblast-based model cell lines (2017) (16)
Modulation of MHC class I surface expression in B16F10 melanoma cells by methylseleninic acid (2017) (16)
Immune modulatory microRNAs as a novel mechanism to revert immune escape of tumors. (2017) (16)
Causes and Consequences of A Glutamine Induced Normoxic HIF1 Activity for the Tumor Metabolism (2019) (15)
Interleukin-1 potently contributes to 25-hydroxycholesterol-induced synergistic cytokine production in smooth muscle cell-monocyte interactions. (2014) (15)
Immune Escape Mechanisms and Their Clinical Relevance in Head and Neck Squamous Cell Carcinoma (2020) (15)
Regulation of beta1 integrin expression by PKCepsilon in renal cancer cells. (2004) (15)
Predictive immunomonitoring -- the COST ENTIRE initiative. (2013) (15)
Cytotoxic T lymphocytes define multiple peptide isoforms derived from the melanoma‐associated antigen MART‐1/Melan‐A (1999) (14)
Multispectral Fluorescence Imaging Allows for Distinctive Topographic Assessment and Subclassification of Tumor-Infiltrating and Surrounding Immune Cells. (2019) (14)
Loss of epithelium-specific GPx2 results in aberrant cell fate decisions during intestinal differentiation (2017) (14)
Gamma interferon regulates long terminal repeat-controlled oncogene expression in transformed mouse fibroblasts at the level of mRNA transcription (1988) (14)
Screening of synthetic and natural product databases: Identification of novel androgens and antiandrogens. (2015) (14)
Tumor-Associated Antigens (2009) (13)
Tumour immunity and T cell memory are induced by low dose inoculation with a non-replicating adenovirus encoding TAP1. (2007) (13)
Promoter methylation of aminopeptidase N/CD13 in malignant melanoma. (2012) (13)
Immunotherapy for metastatic renal cell carcinoma. (2017) (13)
B7‐1 and B7‐2 act differentially in the induction of a T cell response: Their impact for a HLA‐matched and HLA‐mismatched anti‐tumor immunotherapy (2005) (13)
Towards defining biomarkers indicating resistances to targeted therapies. (2014) (13)
Development and characterization of mouse anti-human LMP2, LMP7, TAP1 and TAP2 monoclonal antibodies. (2008) (13)
Comparative expression profiling for human endoplasmic reticulum-resident aminopeptidases 1 and 2 in normal kidney versus distinct renal cell carcinoma subtypes. (2013) (12)
Current Understanding of the HIF-1-Dependent Metabolism in Oral Squamous Cell Carcinoma (2020) (12)
Distinct mechanisms of interferon‐gamma and tumor necrosis factor‐alpha action in oncogene‐transformed mouse fibroblasts (1988) (12)
The common Scandinavian human leucocyte antigen ancestral haplotype 62.1 as prognostic factor in patients with advanced malignant melanoma (2009) (12)
The tumor microenvironment: Thousand obstacles for effector T cells. (2017) (12)
Molecular mechanisms of human herpes viruses inferring with host immune surveillance (2020) (12)
Tumor necrosis factor-alpha affects LTR-controlled oncogene expression in transformed mouse fibroblasts at the post-transcriptional level. (1988) (12)
Differential effect on different immune subsets of neoadjuvant chemotherapy in patients with TNBC (2020) (12)
NF-κB activation triggers NK-cell stimulation by monocyte-derived dendritic cells (2019) (12)
Murine gamma interferon inhibits v-mos-induced fibroblast transformation via down regulation of retroviral gene expression (1987) (12)
What is the prospect of indoleamine 2,3-dioxygenase 1 inhibition in cancer? Extrapolation from the past (2021) (12)
Proteomic and PROTEOMEX profiling of mammary cancer progression in a HER‐2/neu oncogene‐driven animal model system (2010) (11)
Induction of platelet-derived growth factor B/c-sis by the v-erbA oncogene in glial cells. (1995) (11)
Targeting the coding sequence: opposing roles in regulating classical and non-classical MHC class I molecules by miR-16 and miR-744 (2020) (11)
Short-term treatment with gamma interferon induces stable reversion of ras-transformed mouse fibroblasts (1991) (11)
Linkage of microRNA and proteome-based profiling data sets: a perspective for the priorization of candidate biomarkers in renal cell carcinoma? (2011) (11)
Hypoxia-mediated alterations and their role in the HER-2/neuregulated CREB status and localization (2016) (11)
Predominance of TH2 cells and plasma cells in polyoma virus nephropathy: a role for humoral immunity? (2012) (10)
Comprehensive flow cytometric reference intervals of leukocyte subsets from six study centers across Europe (2020) (10)
Survival of the fittest or best adapted: HLA-dependent tumor development (2010) (10)
POST‐TRANSCRIPTIONAL DOWNREGULATION OF MHC CLASS I EXPRESSION IN ONCOGENE‐TRANSFORMED CELLS IS REVERTED BY IFN‐GAMMA AND TNF‐ALPHA (1989) (10)
High PD-L1/CD274 Expression of Monocytes and Blood Dendritic Cells Is a Risk Factor in Lung Cancer Patients Undergoing Treatment with PD1 Inhibitor Therapy (2020) (10)
Analysis of the structural integrity of the TAP2 gene in renal cell carcinoma. (2003) (10)
Thyroid Hormone Receptor / c-erbA : Control of Commitment and Differentiation in the Neuronal / Chromatfin Progenitor Line PC 12 (2002) (9)
Detection of a germline mutation and somatic homozygous loss of the von Hippel-Lindau tumor-suppressor gene in a family with a de novo mutation (1996) (9)
DRH1 – a novel blood-based HPV tumour marker (2020) (9)
B7/CD28 Costimulation of T Cells Induces a Distinct Proteome Pattern* (2005) (9)
Harnessing the immune system for the treatment of melanoma: current status and future prospects (2016) (9)
Expression, Regulation and Function of microRNA as Important Players in the Transition of MDS to Secondary AML and Their Cross Talk to RNA-Binding Proteins (2020) (9)
Fluorescent spherical mesoporous silica nanoparticles loaded with emodin: Synthesis, cellular uptake and anticancer activity. (2021) (9)
T-Cell Activation by Recombinant Receptors : CD 28 Costimulation Is Required for Interleukin 2 Secretion and Receptor-mediated T-Cell Proliferation but Does Not Affect Receptor-mediated Target Cell Lysis 1 (2001) (9)
The non-classical antigens of HLA-G and HLA-E as diagnostic and prognostic biomarkers and as therapeutic targets in transplantation and tumors. (2013) (8)
Sialylation of Human Natural Killer (NK) Cells Is Regulated by IL-2 (2020) (8)
The Role of the Lymphocyte Functional Crosstalk and Regulation in the Context of Checkpoint Inhibitor Treatment—Review (2019) (8)
Endogenous Retroviral–K Envelope Is a Novel Tumor Antigen and Prognostic Indicator of Renal Cell Carcinoma (2021) (8)
Tumor Microenvironment, HLA Class I and APM Expression in HPV-Negative Oral Squamous Cell Carcinoma (2021) (8)
VHL-dependent alterations in the secretome of renal cell carcinoma: Association with immune cell response? (2015) (8)
The prognostic impact of human leukocyte antigen (HLA) class I antigen abnormalities in salivary gland cancer. A clinicopathological study of 288 cases (2013) (8)
Immune Escape Mechanisms of Renal Cell Carcinoma (2007) (8)
The Role of the RNA-Binding Protein Family MEX-3 in Tumorigenesis (2020) (7)
Identification of patient-specific and tumor-shared T cell receptor sequences in renal cell carcinoma patients (2017) (7)
Methylation-specific ligation detection reaction (msLDR): a new approach for multiplex evaluation of methylation patterns (2011) (7)
Characterization of the expression and immunological impact of the transcriptional activator CREB in renal cell carcinoma (2020) (6)
Role of HLA-G in Viral Infections (2022) (6)
Renal cell carcinoma alters endothelial receptor expression responsible for leukocyte adhesion (2016) (6)
Tregs activated by bispecific antibodies (2015) (6)
Altered protein expression pattern in colon tissue of mice upon supplementation with distinct selenium compounds (2017) (5)
Combined CD 28 / CD 3 Secretion and Can Be Integrated Into One Simultaneously Required for Efficient IL-2 Signaling and CD 28 Costimulation Are ζ Recombinant Immunoreceptors : CD 3 Tumor-Specific T Cell Activation (2001) (5)
A novel HLA-A*33 (A*3309) allele in a Caucasian family that differs at protein position 66 from HLA-A*3308. (2007) (5)
A novel HLA‐A*29 allele (A*2916) of a Caucasian relative to an ALL patient containing a point mutation in a putatively conserved region which was identified through the loss of a specific amplificate in a low‐resolution SSP‐PCR kit (2007) (5)
A novel HLA-B*35 (B*3570) allele of a Caucasian family differing with one amino acid mismatch from HLA-B*3503 allele in exon 4. (2007) (5)
Multiplex immunohistochemistry as a novel tool for the topographic assessment of the bone marrow stem cell niche. (2020) (5)
Role of signal transduction and microRNAs on the immunogenicity of melanoma cells (2015) (5)
A novel approach for HLA-A typing in formalin-fixed paraffin-embedded-derived DNA (2014) (5)
Receptor activator of NF-κB (RANK)-mediated induction of metastatic spread and association with poor prognosis in renal cell carcinoma. (2018) (5)
A novel HLA-B*57 (B*5714) allele in a healthy male Caucasian individual. (2008) (5)
Expression and function of CTLA4 in melanoma. (2013) (5)
Immune Interaction Map of Human SARS-CoV-2 Target Genes: Implications for Therapeutic Avenues (2021) (5)
Distinct Molecular Mechanisms of Altered HLA Class II Expression in Malignant Melanoma (2021) (5)
Expression and clinical significance of SARS-CoV-2 human targets in neoplastic and non-neoplastic lung tissues. (2020) (5)
Altered Spatial Composition of the Immune Cell Repertoire in Association to CD34+ Blasts in Myelodysplastic Syndromes and Secondary Acute Myeloid Leukemia (2021) (4)
Methionine and seleno-methionine type peptide and peptoid building blocks synthesized by five-component five-center reactions. (2017) (4)
Identification of Immune Modulatory miRNAs by miRNA Enrichment via RNA Affinity Purification. (2019) (4)
Cumulative suppressive index as a predictor of relapse free survival and overall survival in Human Papilloma Virus‐negative oral squamous cell carcinomas with negative resection margins (2020) (4)
„Immune escape”-Mechanismen von humanen Tumoren (1999) (4)
Human tissue cultures of lung cancer predict patient susceptibility to immune-checkpoint inhibition (2021) (4)
CD 4 1 Tumor-Infiltrating Lymphocytes in Cervical Cancer Recognize HLA-DR-Restricted Peptides Provided by Human Papillomavirus-E 7 (1999) (4)
Impaired HLA‐class‐I stability in a sarcoma cell line which stimulates exclusively HLA‐class‐II‐restricted autologous T cells (1996) (4)
Characterizing CD44 regulatory microRNAs as putative therapeutic agents in human melanoma (2019) (4)
Differential responsiveness to BRAF inhibitors of melanoma cell lines BRAF V600E-mutated (2016) (4)
Granulocyte-to-dendritic cell-ratio as marker for the immune monitoring in patients with renal cell carcinoma (2014) (4)
Correction to: Clinical relevance of the tumor microenvironment and immune escape of oral squamous cell carcinoma (2018) (4)
Induction of pulmonary HLA-G expression by SARS-CoV-2 infection (2022) (3)
c-erbA and v-erbA modulate growth and gene expression of a mouse glial precursor cell line. (1994) (3)
Kallikrein‐related peptidases are activators of the CC chemokine CCL14 (2018) (3)
Synergistic effects of IL-4 and TNFα on the induction of B7-H1 in renal cell carcinoma cells inhibiting allogeneic T cell proliferation (2014) (3)
Recombinant generation of two fragments of the rat complement inhibitory factor H [FH(SCR1-7) and FH(SCR1-4)] and their structural and functional characterization in comparison to FH isolated from rat serum. (2006) (3)
A novel HLA‐A*0119 allele of a Caucasian family containing a mutation in a highly conserved region (2006) (3)
The Human Leukocyte Antigen G as an Immune Escape Mechanism and Novel Therapeutic Target in Urological Tumors (2022) (3)
A novel HLA-B70 (B*9514) allele with an amino acid substitution (alanine to glycine at protein position 139) in a Caucasian heart allograft recipient. (2006) (3)
Relevance of 2′-O-Methylation and Pseudouridylation for the Malignant Melanoma (2021) (3)
Identification of a novel miR‐21‐3p/TGF‐β signaling‐driven immune escape via the MHC class I/biglycan axis in tumor cells (2021) (3)
Immunotherapy of Breast Cancer (2018) (3)
The HHV-6A Proteins U20 and U21 Target NKG2D Ligands to Escape Immune Recognition (2021) (3)
An altered miTRAP method for miRNA affinity purification with its pros and cons. (2019) (3)
Correlation of the tumor mutational burden with the composition of the immune cell subpopulations in peripheral blood of triple-negative breast cancer patients undergoing neoadjuvant therapy with durvalumab: Results from the prospectively randomized GeparNuevo trial. (2019) (2)
B7-H abnormalities in melanoma and clinical relevance. (2014) (2)
Underlying mechanisms of evasion from NK cells as rationale for improvement of NK cell-based immunotherapies (2022) (2)
Stable expression of a selectable myeloproliferative sarcoma virus in murine T lymphocyte and monocyte cell lines. (1987) (2)
Impact of the mitogen‐activated protein kinase pathway on the subproteome of detergent‐resistant microdomains of colon carcinoma cells (2015) (2)
HLA-G-specific microRNAs a novel approach for targeting tumors (2013) (2)
Blood Immune Cell Biomarkers in Lung Cancer Patients Undergoing Treatment with a Combination of Chemotherapy and Immune Checkpoint Blockade (2022) (2)
Major Histocompatibility Complex Modulation and Loss (2003) (2)
In vitro models as tools for screening treatment options of head and neck cancer (2022) (2)
A Chimeric IL-15/IL-15Rα Molecule Expressed on NFκB-Activated Dendritic Cells Supports Their Capability to Activate Natural Killer Cells (2021) (2)
Oncogene Transformation can induce Tolerogenicity in Murine Macrophages after Down‐Regulation of Immunogenicity without altering Major Histocompatibility Complex Antigen Expression (1993) (2)
Opposing consequences of signaling through EGF family members (2012) (2)
Receptor activator of NFκB (RANK)-mediated induction of metastatic spread and association with poor prognosis in renal cell carcinoma (2017) (2)
“Tumor Immunology Meets Oncology (TIMO) IX”, May 2–4, 2013, Halle/Saale, Germany (2014) (2)
1019: PKC Epsilon Regulates Beta-1 Integrin Expression but Not Migration of Renal Cancer Cells (2004) (2)
PIR-B expressing CD8+ T cells exhibit features of Tc1 and Tc17 in SKG mice. (2019) (2)
Monoallelic expression in melanoma (2016) (2)
HLA-dependent tumour development: a role for tumour associate macrophages? (2013) (1)
Immunological properties of the murine macrophage cell line P388D1 and its oncogene transfectants in the induction of alloresponses. (1990) (1)
Abstract PD9-04: Immunological and clinical consequences of durvalumab treatment in combination to neoadjuvant chemotherapy in triple-negative breast cancer patients (2023) (1)
Novel role of a tyrosine kinase inhibitor by reversion of immune suppression in renal cell carcinoma. (2010) (1)
Assessment of the tumor immune-environment in patients with head and neck cancer (2015) (1)
The Role of Immune Modulatory MicroRNAs in Tumors (2016) (1)
Abstract 5261: Platelet-Depletion Ameliorates Cardiac Function and Disease Severity in Experimental Autoimmune Myocarditis (2008) (1)
Expression in Human Gliomas , and Epidermal Growth Factor and Their α Growth Factor Genes for Epidermal Growth Factor Receptor , Transforming Updated (2006) (1)
High constitutive B7-H3 expression on human keratinocytes supports T cell immunity. (2017) (1)
Identification and characterization of novel CD274 (PD‐L1) regulating microRNAs and their functional relevance in melanoma (2022) (1)
Regulation of Major Histocompatibility Complex Class I Gene Expression in Oncogene-Transformed Mouse Fibroblasts1 (1994) (1)
“Tumor immunology meets oncology” (TIMO) XI, May 22–23, 2015, Halle/Saale, Germany (2014) (1)
“Tumor immunology meets oncology IV”, 23rd and 24th May 2008 Martin Luther University Halle-Wittenberg, Halle, Germany (2010) (1)
Modulation of Lymphocyte Functions in the Microenvironment by Tumor Oncogenic Pathways (2022) (1)
Transcriptional Analysis of Total CD8+ T Cells and CD8+CD45RA- Memory T Cells From Young and Old Healthy Blood Donors (2022) (1)
Thrombospondin-2 and LDH Are Putative Predictive Biomarkers for Treatment with Everolimus in Second-Line Metastatic Clear Cell Renal Cell Carcinoma (MARC-2 Study) (2021) (1)
Biomarker Discovery in Renal Cell Carcinoma Applying Proteome‐Based Studies in Combination with Serology (2006) (1)
Influence of oncogenes and cell metabolism on immunogenicity and tolerogenicity of a model macrophage cell line. (1993) (1)
“Tumor Immunology Meets Oncology (TIMO) VIII” from May 4 to 5, 2012, in Halle/Saale, Germany (2012) (1)
Cancer Immunology: Immune Escape of Tumors-Expression and Regulation of HLA Class I Molecules and Its Role in Immunotherapies. (2022) (1)
Immunomonitoring of triple negative breast cancer patients undergoing neoadjuvant therapy (GBG89, Geparnuevo trial). (2018) (1)
Translational analysis and final efficacy of the AVETUX trial – Avelumab, cetuximab and FOLFOX in metastatic colorectal cancer (2022) (1)
Modulation of immune cell subpopulations in renal cell carcinoma patients by sunitinib. (2011) (1)
“Tumor immunology meets oncology” (TIMO) X, May 23–24, 2014, Halle/Saale, Germany (2015) (1)
Cytokine-induced delivery of the costimulatory signal for a v-mos-transfected nonallostimulating, MHC I+II+ clone of the murine macrophage cell line P388D1 and induction of tolerance. (1991) (1)
Publisher Correction: Immunoprophylactic and immunotherapeutic control of hormone receptor-positive breast cancer (2020) (1)
Candidate biomarkers in renal cell carcinoma. (2011) (1)
Ubiquitin carboxylterminal hydrolase-1: A biomarker of renal cell carcinoma and melanoma (2006) (1)
Expression and Clinical Significance of SARS-CoV-2 Human Targets in Lung Tissues: Normal, Primary Tumor and Metastasis (2020) (0)
Proteomic and PROTEOMEX profiling of mammary cancer progression in a HER‐2/neu oncogene‐driven animal model system (2011) (0)
Humoral Immune Responses against Cancer Antigens: Serological Identification Methods. Part II: Proteomex and AMIDA (2009) (0)
828 Improved growth properties and immune surveillance in K-RAS G12V-transformed cells through overexpression of biglycan (2020) (0)
Hidden anti-HLA antibodies and B-cell x-match results (2004) (0)
1144 IL17-producing γδ T cells promote resistance to CDK4/6 inhibitors in HR+HER2-breast cancer (2022) (0)
Role of signal transduction and microRNAs on the immunogenicity of melanoma cells (2015) (0)
Immune interaction map of human SARS-CoV-2 target proteins: implications for therapeutic avenues (2020) (0)
Evaluation of TCR amplification in tumor lesions and peripheral blood of renal cell carcinoma patients (2013) (0)
“Tumor immunology meets oncology (TIMO) XII”, April 28th–30th 2016, Halle/Saale, Germany (2017) (0)
HLA Class I Antigen Abnormalities in Tumors (2007) (0)
Update Breast Cancer 2022 Part 1 – Early Stage Breast Cancer (2022) (0)
“Tumor immunology meets oncology (TIMO) VI” from 7th to 8th of May 2010 in Halle, Germany (2011) (0)
Molecule Signaling Receptor ζ Combined CD28/CD3 Secretion and Can Be Integrated Into One Simultaneously Required for Efficient IL-2 Signaling and CD28 Costimulation Are ζ Recombinant Immunoreceptors: CD3 Tumor-Specific T Cell Activation by (2017) (0)
Discrimination between Von Hippel-Lindau gene and hypoxia-regulated alterations in the metabolism and protein expression in renal cell carcinoma using ome-based strategies. (2014) (0)
CLASS I MOLECULES - ENEMIES OR FRIENDS POTENTIAL IMMUNE ESCAPE MECHANISMS OF TUMORS: MHC (2008) (0)
“Tumor Immunology Meets Oncology (TIMO) XIV”, May 24–26th 2018, Halle/Saale, Germany (2019) (0)
Future perspectives in melanoma research: meeting report from the “Melanoma Bridge”: Napoli, December 3rd–6th 2014 (2015) (0)
Potentiation of Growth Inhibition and Modulation of Differentiation in Human Malignant Glioblastomas by Combined Treatment with Recombinant Human Interferon-α and -γ1 (1994) (0)
What is the prospect of indoleamine 2,3-dioxygenase 1 inhibition in cancer? Extrapolation from the past (2021) (0)
Potential Immune Escape Mechanisms of Tumors: MHC Class I Molecules – Enemies or Friends (2008) (0)
Molecular and cytogenetic studies on sporadic and familial forms of renal cell carcinomas : Detection of homozygous loss of the Von Hippel-Lindau tumor-suppressor gene by cytogenetics, PCR/SSCP, FISH with 3p YAC probes and CGH (1995) (0)
in Human Breast Cancer Cell Lines Chain-Related Molecule A and B Expression Cell-Mediated Cytotoxicity via MHC Class I HER2/HER3 Signaling Regulates NK (2012) (0)
Tumor immunity and immunosurveillance (PP-093) (2010) (0)
Role of miRs in immune suppression (2014) (0)
Effect of sorafenib on protein expression profiles in melanoma. (2011) (0)
Identification of immunomodulatory RNA-binding proteins in tumors. (2020) (0)
Interferons and Resistance Mechanisms in Tumors and Pathogen-Driven Diseases—Focus on the Major Histocompatibility Complex (MHC) Antigen Processing Pathway (2023) (0)
Biology of Human Tumors Inhibition of Tumor-Derived Prostaglandin-E 2 Blocks the Induction ofMyeloid-DerivedSuppressorCells andRecovers Natural Killer Cell Activity (2014) (0)
Contribution of interleukin-22, a T cell secreted cytokine, to renal cell carcinoma progression and association with poor outcome in RCC patients. (2016) (0)
119 Interleukin-22 (IL-22), a T-cell secreted cytokine, contributes to renal cell carcinoma (RCC) progression and is associated with poor outcome in RCC patients (2016) (0)
Abstract 641: Effects of an mTOR inhibitor on immune subpopulations (2011) (0)
Biglycan as a potential regulator of tumorgenicity and immunogenicity in K-RAS-transformed cells (2022) (0)
Sunday 8 – Tuesday 10 July 2012Poster SessionExperimental / Molecular Therapeutics, Pharmacogenomics987 Molecular Mechanisms of Sorafenib-induced Apoptosis in Cancer Cells (2012) (0)
Survival rates in HLA-A2 positive patients, with stage III-IV serous adenocarcinomas of the ovary, correlates with increased expression of COX-2 and iNOS, loss of MHC Class I and II and defects of the antigen processing mechanisms at the tumour level (2008) (0)
Characterization of the expression and immunological impact of the transcriptional activator CREB in renal cell carcinoma (2020) (0)
This information is current as Alteration in the Peptide TAP Subunit TAP1 Attributable to a Single Amino Acid Antigen Processing (TAP) Function Impaired Transporter Associated with (2013) (0)
DKFZ-MOST Cooperation in Cancer Research (2016) (0)
HER-2/neu immunotherapies: Take two – get more: optimization strategies for HER-2/neu-based immunotherapies inhibiting carcinogenesis (2004) (0)
Cellular Aging and Tumor Regulation (2016) (0)
Identification and characterization of human leukocyte antigen class I ligands in renal cell carcinoma cells (2011) (0)
Identification of a novel lncRNA induced by the nephrotoxin ochratoxin A and expressed in human renal tumor tissue (2017) (0)
“UniCAR”-modified off-the-shelf NK-92 cells for targeting of GD2-expressing tumour cells (2020) (0)
Short-Term Treatment withGamma Interferon InducesStable Reversion ofras-Transformed MouseFibroblasts (1991) (0)
Correction to: Clinical relevance of the tumor microenvironment and immune escape of oral squamous cell carcinoma (2018) (0)
910 Overexpression of miR-155–5p can upregulate antigen processing and presentation pathway via targeting tapasin (2021) (0)
Immune escape mechanisms associated with tumor recurrence after adoptive cell transfer immunotherapy. (2014) (0)
Abstract B020: Antiproliferative efficacy of different targeted drugs on breast cancer cell lines of distinct subtypes (2020) (0)
Abstracts from the 4th ImmunoTherapy of Cancer Conference (2017) (0)
Abstract P1-08-34: Peripheral immunity predicts therapeutic outcomes in breast cancer patients (2022) (0)
A vision of immuno-oncology: the Siena think tank of the Italian network for tumor biotherapy (NIBIT) foundation (2021) (0)
Rediscovering an old story: HLA class I alterations and immune escape of tumors in the context of immunotherapies (2018) (0)
“Tumor immunology meets oncology (TIMO) XV”, April 25th–27th 2019, Halle/Saale, Germany (2020) (0)
Enhanced function of vaccine dendritic cells from obese donors upon inhibition of the lipid metabolism (2022) (0)
868 PRELP-facilitated enhancement of MHC class I surface expression in B16F10 melanoma cells (2020) (0)
Brahmaraju Mopidevi , Madhusudhan Ponnala and Ashok Kumar binding modulates its gene expression through microRNA Human angiotensinogen + 11525 C / A polymorphism (2013) (0)
Interferone und Onkogene (1990) (0)
Future perspectives in melanoma research: meeting report from the "Melanoma Bridge", Napoli, December 5th-8th 2013 (2014) (0)
Abstract C031: NanoString nCounter-based gene expression assay for evaluation of breast cancer molecular subtypes in Ethiopian patients (2020) (0)
Different maturation cocktails provide dendritic cells with different chemoattractive properties (2015) (0)
Human Papillomavirus-E 7 HLA-DR-Restricted Peptides Provided by Cervical Cancer Recognize Tumor-Infiltrating Lymphocytes in + CD 4 Seliger and (1999) (0)
Tumor-Killing Capabilities of Innate and Adaptive Effector Cells with Polyfunctional and Long-Lasting Activation Alternative Maturation Mixtures Induce Fast Dendritic Cells Stimulated with (2013) (0)
Therapy resistance in renal cell carcinoma correlates with an endothelial cell-dependent altered immune cell infiltrate (2018) (0)
Altered expression proteins involved in cytoskeletal formation and metabolic pathways in renal cell carcinoma linked to microRNA expression. (2011) (0)
Future perspectives in melanoma research. Meeting report from the “Melanoma Bridge. Napoli, December 2nd-4th 2012” (2013) (0)
856: Molecular mechanisms of sorafenib-induced apoptosis in cancer cells (2014) (0)
CREB1 is affected by the microRNAs miR-22-3p, miR-26a-5p, miR-27a-3p, and miR-221-3p and correlates with adverse clinicopathological features in renal cell carcinoma (2020) (0)
Esophageal and Gastric Cancer Regulator of HLA-A Expression in The MAPK Pathway Is a Predominant (2013) (0)
Human tissue cultures of lung cancer predict patient susceptibility to immune-checkpoint inhibition (2021) (0)
Viral Transfer, Transcription, andRescueofaSelectable Myeloproliferati ve Sarcoma Virus inEmbryonal CellLines: Expression ofthemosOncogene (1986) (0)
151P Tumor biology and immunology in patients (pts) with breast cancer occurring during pregnancy (BCP) compared to non-pregnant breast cancer pts (2022) (0)
What turns CREB on? And off? And why does it matter? (2020) (0)
Novel approach to identify putative Epstein–Barr–virus microRNAs regulating host cell genes with relevance in tumor biology and immunology (2022) (0)
MicroRNAs affecting the susceptibility of melanoma cells to CD8+ T cell‐mediated cytolysis (2023) (0)
Differential7-lnterferon Responseof HumanColonCarcinomaCells: Inhibition of Proliferationand Modulationof Immunogenicityas IndependentEffects of 7-lnterferon on TumorCell Growth1 (2006) (0)
Reports of Oncological Societies (2014) (0)
Interleukin-22, a T cell secreted cytokine, contributes to renal cell carcinoma progression and is associated with poor outcome in RCC patients (2016) (0)
“Tumor immunology meets oncology (TIMO) VII” from 15th to 16th of April 2011 in Halle/Saale, Germany (2011) (0)
Biglycan as a mediator of proinflammatory response and target for MDS and sAML therapy (2022) (0)
Defects in the Human LeukocyteAntigen Class I Antigen-Processing Machinery in Head and Neck Squamous Cell Carcinoma : Associationwith Clinical Outcome (2005) (0)
Hydrogen peroxide – production, fate and role in redox signaling of tumor cells (2015) (0)
[Molecular biology in hematology/oncology]. (1994) (0)
Deficiencies of the MHC Class I Antigen Processing and Presentation Machinery in Tumor Cells (1997) (0)
Molekulare Diagnostik bei soliden Tumoren (2014) (0)
Phänotypisierung von Tumorzellen (2007) (0)
Regional variation in the tumor microenvironment, immune escape and prognostic factors in breast cancer in sub-Saharan Africa. (2023) (0)
Tumor-Size-Dependent Remission Tumor Model Leads to Apoptosis and Switching Off HER-2 / neu in a Tetracycline-Controlled Mouse (2003) (0)
PD57-06 ALTERED IMMUNE CELL REPERTOIRE AND ACTIVITY AFTER CHECKPOINT BLOCKADE IMMUNOTHERAPY WITH NIVOLUMAB IN RENAL CELL CARCINOMA (2018) (0)
Signal Transduction HER-2 / neu Mediates Oncogenic Transformation via Altered CREB Expression and Function (2013) (0)
Peripheral Blood Monocyte Abundance Predicts Outcomes in Patients with Breast Cancer (2022) (0)
Tumoral HLA Class I and APM Expression and Its Effect on Intratumoral T-cell Reaction and Outcome in HPV-Negative Oral Squamous Cell Carcinoma (2020) (0)
Abstract P4-06-01: Immunomonitoring of triple negative breast cancer patients undergoing neoadjuvant therapy with durvalumab - Results from the prospectively randomized GeparNuevo trial (2019) (0)
Tnf-mediated inhibition of transformation of mouse fibroblasts correlates with down-regulation of oncogene expression (1987) (0)
Prinzipien der Tumorimmunologie (1996) (0)
Abstract 2172: Effects of RAD001 on the protein expression pattern and function of tumor and immune cells. (2013) (0)
Abstract 4087: Identification of microRNAs involved in shaping immune surveillance and growth properties of tumors (2014) (0)
Abstract 993: Epigenetic immune cell profiling in B-non-Hodgkin lymphoma biopsies (2023) (0)
Characterization of the effect of histone deacetylation inhibitors on CD8+ T cells in the context of aging (2022) (0)
TAP1 Subunit Alteration in the Peptide TAP Attributable to a Single Amino Acid Antigen Processing (TAP) Function Impaired Transporter Associated with (2010) (0)
Altered Spatial Composition of the Immune Cell Repertoire in the Bone Marrow Stem Cell Niche in Myelodysplastic Syndromes and Secondary Acute Myeloid Leukemia (2020) (0)
Update Mammakarzinom 2022 Teil 1 – Brustkrebs in frühen Krankheitsstadien (2022) (0)
Abstract 1278: Accumulation of tolerogenic human 6-sulfo LacNAc+ dendritic cells in renal cell carcinoma is associated with poor prognosis (2015) (0)
Correction: Renal cell carcinoma alters endothelial receptor expression responsible for leukocyte adhesion (2017) (0)
Antigen processing and presentation (PP-026) (2010) (0)
PROTEOMEX Analysis of Renal Cell Carcinoma (2009) (0)
Human leucocyte antigen class I in hormone receptor-positive, HER2-negative breast cancer: association with response and survival after neoadjuvant chemotherapy (2019) (0)
HER‐2 as a Tumor Antigen (2009) (0)
Mortality factors in pancreatic surgery: A systematic review. How important is the hospital volume? (2022) (0)
Differential responsiveness to BRAF inhibitors of melanoma cell lines BRAF V600E-mutated (2020) (0)
Molekulare Diagnostik bei soliden Tumoren (2014) (0)
Alterations Of The Tumor Microenvironment By Her-2-neu-induced Creb Activation And Localization And Hypoxia (2014) (0)
GammaInterferon Regulates LongTerminal Repeat-Controlled Oncogene Expression inTransformed MouseFibroblasts atthe LevelofmRNA Transcription (1988) (0)
International Symposium on Cancer Immunotherapy: Featuring Today's Innovators, Tomorrow's Leaders (2015) (0)
Immune-escape-Mechanismen und Resistenzen gegenüber Immuntherapien (2019) (0)
Clinical relevance of the tumor microenvironment and immune escape of oral squamous cell carcinoma (2016) (0)
Monoallelic expression in melanoma (2019) (0)
Peripheral Blood Monocyte Abundance Predicts Outcomes in Breast Cancer Patients (2021) (0)
Abstract 1808: Modulation of the immune cell repertoire and immunogenicity of tumor cells by sorafenib (2010) (0)
Role of the Non-classical HLA Class I Antigens for Immune Escape (2015) (0)
Abstract 1799: Hypoxia-induced alterations of renal cell carcinoma cells and their modulation by tyrosine kinase inhibitors (2012) (0)
Fluvastatin reverses lps-hyporesponsiveness in a monocyte-smc vs. macrophage-smc coculture model (2014) (0)
Association of IFN-g Signal Transduction Defects with Impaired HLA Class I Antigen Processing in Melanoma Cell Lines (2011) (0)
Monitoring Blood Immune Cells in Patients with Advanced Small Cell Lung Cancer Undergoing a Combined Immune Checkpoint Inhibitor/Chemotherapy (2023) (0)
Molekularbiologie und Immunologie des Nierenzellkarzinoms (2001) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Barbara Seliger?

Barbara Seliger is affiliated with the following schools:

Barbara Seliger's Academic­Influence.com Rankings